CDH2 and breast cancer: Meanwhile, another recent report has shown that cryptotanshinone, as a novel pyruvate dehydrogenase kinase 4 inhibitor, reduced the BC cell invasion capacity by regulating the mammalian target of rapamycin/β-catenin/N-cadherin signaling pathway [44].